CPC A61K 38/179 (2013.01) [A61P 9/00 (2018.01); A61P 9/10 (2018.01); A61P 19/10 (2018.01); C07K 14/71 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01)] | 26 Claims |
1. A method for treating a disease in a subject, comprising administering to the subject a pharmaceutically effective dose of an activin receptor type II (ActRII) signaling inhibitor, wherein the subject has:
(a) elevated levels of snail homolog 1 (Snai1) as compared to levels of Snai1 in a reference population;
(b) decreased levels of alpha smooth muscle actin (alpha-SMA) as compared to levels of alpha-SMA in a reference population;
(c) elevated levels of urinary protein as compared to levels of urinary protein in a reference population; and/or
(d) decreased levels of Axin2 as compared to levels of Axin2 in a reference population,
wherein the disease is:
(a) cardiovascular disease;
(b) vascular calcification;
(c) cardiovascular disease associated with and/or resulting from vascular calcification;
(d) arterial stiffness;
(e) cardiovascular disease associated with and/or resulting from arterial stiffness;
(f) left ventricular hypertrophy (LVH);
(g) cardiovascular disease associated with and/or resulting from left ventricular hypertrophy;
(h) cardiovascular disease associated with and/or resulting from renal disease; or
(i) bone resorption associated with chronic kidney disease-mineral and bone disease (CKD-MBD), and
wherein said ActRII signaling inhibitor comprises an amino acid sequence that is
(a) at least 98% identical to SEQ ID NO:2;
(b) at least 98% identical to SEQ ID NO:3;
(c) at least 98% identical to SEQ ID NO:6;
(d) at least 98% identical to SEQ ID NO:7; or
(e) at least 98% identical to SEQ ID NO:12.
|